Cryo Cell International vs Joint
Joint is the larger business, with $54.9m of revenue in fiscal 2025 against $31.6m for Cryo Cell International (1.7 times as much). Joint grew faster (5.2% against -1.3%). Joint kept more of each dollar of sales as profit: a net margin of 5.3% against -7.7%.
| Latest fiscal year | Cryo Cell InternationalCCEL, 2025 | JointJYNT, 2025 |
|---|---|---|
| Revenue | $31.6m | $54.9m |
| Revenue growth | -1.3% | 5.2% |
| Net income | −$2.4m | $2.9m |
| Operating margin | 1.5% | -1.7% |
| Net margin | -7.7% | 5.3% |
| Return on equity | — | 16.3% |
| Free cash flow | $5.2m | $334,724 |
| Cash | $319,031 | $23.6m |
| Total debt | $10.7m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | $169,502 | $11.3m |
| Employees | 72 | — |
| Market value | $40.7m | $103m |
| Price vs our value range | Below our value range | Above our value range |
| Moat score | 73 (Strong) | 59 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 15 buys, 0 sales |